• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Mineralys Therapeutics Inc.

    2/13/26 4:30:03 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLYS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Mineralys Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    603170101

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    603170101


    1Names of Reporting Persons

    Catalys Pacific Fund, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,002,738.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,002,738.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,002,738.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    603170101


    1Names of Reporting Persons

    Catalys Pacific Fund GP, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,002,738.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,002,738.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,002,738.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    603170101


    1Names of Reporting Persons

    Catalys Pacific, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,002,738.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,002,738.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,002,738.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    603170101


    1Names of Reporting Persons

    Brian Taylor Slingsby
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,002,738.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,002,738.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,002,738.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Mineralys Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    150 N. Radnor Chester Rd, Suite F200, Radnor, PA 19087
    Item 2. 
    (a)Name of person filing:

    Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: Catalys Pacific Fund, LP Catalys Pacific Fund GP, LP Catalys Pacific, LLC Brian Taylor Slingsby
    (b)Address or principal business office or, if none, residence:

    The principal business address for Catalys Pacific Fund, LP, Catalys Pacific Fund GP, LP and Catalys Pacific, LLC is IQ EQ Corporate Services (Cayman) Limited, 3rd Floor Whitehall House, 238 North Church Street, Grand Cayman, Cayman Islands. The principal business address for Brian Taylor Slingsby is 1700 Westlake Avenue N, Suite 200, Thinkspace, Seattle, WA 98109.
    (c)Citizenship:

    Brian Taylor Slingsby is a citizen of the United States. The other Reporting Persons are each entities organized under the laws of the Cayman Islands.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    603170101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2025, based upon 79,139,956 shares of Common Stock outstanding as of November 3, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2025. Catalys Pacific Fund, LP is the beneficial owner of 8,002,738 shares of Common Stock, which includes 7,903,838 shares of Common Stock held of record by Catalys Pacific Fund, LP and 98,900 shares of Common Stock underlying stock options that are exercisable within 60 days of December 31, 2025. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing director of Catalys Pacific, LLC. As a result, each of the Reporting Persons may be deemed to share beneficial ownership over the securities reported herein.
    (b)Percent of class:

    10.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    8,002,738

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    8,002,738

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Catalys Pacific Fund, LP
     
    Signature:By: Catalys Pacific Fund GP, LP, its General Partner, By: Catalys Pacific, LLC, its General Partner, By: /s/ Brian Taylor Slingsby
    Name/Title:Brian Taylor Slingsby, Managing Director
    Date:02/13/2026
     
    Catalys Pacific Fund GP, LP
     
    Signature:By: Catalys Pacific, LLC, its General Partner, By: /s/ Brian Taylor Slingsby
    Name/Title:Brian Taylor Slingsby, Managing Director
    Date:02/13/2026
     
    Catalys Pacific, LLC
     
    Signature:/s/ Brian Taylor Slingsby
    Name/Title:Brian Taylor Slingsby, Managing Director
    Date:02/13/2026
     
    Brian Taylor Slingsby
     
    Signature:/s/ Brian Taylor Slingsby
    Name/Title:Brian Taylor Slingsby
    Date:02/13/2026
    Get the next $MLYS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLYS

    DatePrice TargetRatingAnalyst
    6/11/2025$15.00Hold
    Jefferies
    7/10/2024$30.00Buy
    H.C. Wainwright
    4/2/2024$30.00Buy
    Goldman
    3/7/2023Outperform
    Evercore ISI
    3/7/2023$39.00Buy
    BofA Securities
    3/7/2023$32.00Buy
    Guggenheim
    3/7/2023$27.00Overweight
    Wells Fargo
    3/7/2023$45.00Buy
    Stifel
    More analyst ratings

    $MLYS
    SEC Filings

    View All

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    3/17/26 5:04:58 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Mineralys Therapeutics Inc.

    144 - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    3/13/26 4:50:02 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Mineralys Therapeutics Inc.

    10-K - Mineralys Therapeutics, Inc. (0001933414) (Filer)

    3/12/26 5:19:05 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $14,999,992 worth of shares (588,235 units at $25.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    9/8/25 8:07:14 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $29,999,985 worth of shares (1,176,470 units at $25.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    9/8/25 5:59:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Slingsby Brian Taylor bought $3,499,996 worth of shares (259,259 units at $13.50) (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    4/25/25 7:01:59 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rodman David Malcom sold $10,696 worth of shares (417 units at $25.65) and exercised 417 shares at a strike of $15.44 (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/17/26 4:51:17 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rodman David Malcom exercised 14,057 shares at a strike of $7.28 and sold $542,973 worth of shares (20,406 units at $26.61), decreasing direct ownership by 8% to 76,140 units (SEC Form 4)

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/16/26 5:20:12 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mineralys Therapeutics Inc.

    4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer)

    3/10/26 5:48:35 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on March 16, 2026, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to a new non-executive employee. The awards were granted under Mineralys' 2025 Employment Inducement Incentive Awa

    3/16/26 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

    –  Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. "Mineralys had a transformational year in 2025, defined by significan

    3/12/26 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

    – The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with hypertension – – Topline results from the Phase 2 Explore-OSA exploratory trial did not reduce AHI; demonstrated a clinically meaningful reduction in blood pressure and favorable safety and tolerability in this population with difficult to control hypertension – RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic

    3/9/26 4:30:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Mineralys Therapeutics with a new price target

    Jefferies initiated coverage of Mineralys Therapeutics with a rating of Hold and set a new price target of $15.00

    6/11/25 7:54:20 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Mineralys Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    7/10/24 7:50:59 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Mineralys Therapeutics with a new price target

    Goldman initiated coverage of Mineralys Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/24 7:34:24 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Financials

    Live finance-specific insights

    View All

    Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

    –  Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. "Mineralys had a transformational year in 2025, defined by significan

    3/12/26 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

    RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2025, after the financial markets close on Thursday, March 12, 2026. Thursday, March 12th @ 4:30 p.m. ETDomestic:1-877-704-4453International:1-201-389-0920Conference ID:13758574Webcast:Link A live webcast of the conference call may also be found on the "News & Eve

    3/9/26 8:00:00 AM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    – Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are at an excitin

    11/10/25 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:27:48 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:19:46 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mineralys Therapeutics Inc.

    SC 13G/A - Mineralys Therapeutics, Inc. (0001933414) (Subject)

    11/13/24 4:09:56 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLYS
    Leadership Updates

    Live Leadership Updates

    View All

    Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

    RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer. "With our expanding operations, we have decided to split the functions of Chief Financial Officer and Chief Business Officer into two roles, and we are excited to have Minji join our team. She brings a solid track record of generating value for multiple companies by identify

    1/4/24 4:05:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

    LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch ("Praxis"), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer's Disease, today announced the appointment of Adam Levy to its Board of Directors (the "Board"). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals. "We are excited to have Adam join our Board and support our mission to improve the lives of patients with Alzheimer's Disease," said Sandeep Patil, MD PhD, chief executive officer of Praxis Bioresearch. "Adam brings an impressive

    9/19/23 4:00:00 PM ET
    $MLYS
    Biotechnology: Pharmaceutical Preparations
    Health Care